circadian rhythm comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-31. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
=== Food safety === In 2015, the Food and Drug Administration alerted the public that products containing "cake batter" ice cream sold at Cold Stone Creamery stores may be associated with an outbreak of [salmonella] infection in several states. In response, Cold Stone Creamery has agreed to immediately remove all "cake batter" ice cream products from its stores throughout the US.
== Bioart == Gibson gave a talk to the International Society for Anthrozoology (ISAZ) at Cambridge University in July 2012 about the use of live insects in art and entertainment. On 8 February 2017 Gibson walked naked in front of the Vancouver Law Courts in the middle of winter to protest Canada's ban of genetic engineering of the human genome. He walked nude in downtown Vancouver for 11 minutes, 45.75 seconds in a light rain and a temperature of 7 degrees Celsius (45 °F).
Approximately 152,000 such individuals participated in the plebiscite. However, debate went on whether it was a Polish or German condition at Versailles, since it might have been expected that many Ruhr Area Poles would vote for Poland as well. Therefore, it is also reported that the Polish delegation planned to bring Polish émigrés not only from other parts of Germany, but also from America, to the plebiscite area to strengthen their position, but those plans were not executed. The Polish delegation claimed that was a German condition. According to Richard K. Debo, both the German and the Polish governments believed that the outcome of the plebiscite had been decided by the ongoing Polish-Bolshevik War, which threatened the very existence of the newly-formed Polish state itself and so many Poles in the region voted for Germany for fear that if the area joined Poland, it would soon fall under Soviet rule. During the plebiscite, the Red Army came closer to Warsaw every day and committed crimes against the civilian population. According to several Polish sources, the Germans engaged in a massive persecution of Polish activists and their Masurian supporters and went as far as engaging in regular hunts and murder to influence the vote. The organisation of the plebiscite was also influenced by Britain, which supported Germany out of fear of an increased power for France in postwar Europe. According to Jerzy Minakowski, terror and their unequal status made Poles boycott the preparations for the plebiscite, which allowed the Germans to add ineligible voters.
Collectivistic cultures are more likely to use norms and the social appraisals of others in evaluating their subjective well-being, whereas those [individualistic] societies are more likely to heavily weight the internal [frame of reference] arising from one's own happiness.
Sources: en.wikipedia.org
=== Walter Bennett === Dr. Walter Bennett (voiced by Harry S. Robins) is a Black Mesa scientist. He is seen in Half-Life: Blue Shift. In Blue Shift, Dr. Bennett is seen fixing a battery in Dr. Rosenberg's office, along with Dr. Simmons. The three scientists soon get it fixed with the help of Barney Calhoun, and they start their teleportation out of Black Mesa. The four successfully make it out of the facility, making Dr. Bennett one of the few known survivors of the incident. They open the gates and start their journey to the outside world with an SUV. Dr. Bennett is briefly mentioned in Half-Life: Opposing Force. As Adrian Shephard traverses within Sector E of Black Mesa, he enters a testing laboratory where Xen specimens were being experimented on prior to the Resonance Cascade. He opens up a transmission intended for Dr. Bennett, revealing a hologram of a scientist talking about the results of an experiment conducted on a Barnacle, which was one of the Xen creatures being examined. Following the transmission, Shephard takes a nearby Barnacle specimen that was intended for Dr. Bennett to experiment on before the Resonance Cascade. Dr. Bennett's final fate is unknown.
Cholecystokinin tetrapeptide (CCK-4, tetragastrin, Trp-Met-Asp-Phe-NH2) is a peptide fragment derived from the larger peptide hormone cholecystokinin. Unlike cholecystokin which has a variety of roles in the gastrointestinal system as well as central nervous system effects, CCK-4 acts primarily in the brain as an anxiogenic, although it does retain some GI effects, but not as much as CCK-8 or the full length polypeptide CCK-58. CCK-4 reliably causes severe anxiety symptoms when administered to humans in a dose of as little as 50 μg, and is commonly used in scientific research to induce panic attacks for the purpose of testing new anxiolytic drugs. Since it is a peptide, CCK-4 must be administered by injection, and is rapidly broken down once inside the body so has only a short duration of action, although numerous synthetic analogues with modified properties are known.
== Post-war == Residing in Johannesburg, South Africa, Wilson is currently involved in business and conservation initiatives where he consults to various organisations. He is actively involved in efforts to rewild rare and endangered species and engage with community owned conservation projects in order to liberate sustainability out of protected areas in Southern and West Africa.
=== Photodetector === A graphene/n-type silicon heterojunction has been demonstrated to exhibit strong rectifying behavior and high photoresponsivity. By introducing a thin interfacial oxide layer, the dark current of graphene/n-Si heterojunction has been reduced by two orders of magnitude at zero bias. At room temperature, the graphene/n-Si photodetector with interfacial oxide exhibits a specific detectivity up to 5.77 × 1013 cm Hz1/2 W2 at the peak wavelength of 890 nm in vacuum. In addition, the improved graphene/n-Si heterojunction photodetectors possess high responsivity of 0.73 A W−1 and high photo-to-dark current ratio of ≈107. These results demonstrate that graphene/Si heterojunction with interfacial oxide is promising for the development of high detectivity photodetectors. Recently, a graphene/si Schottky photodetector with record-fast response speed (< 25 ns) from wavelength 350 nm to 1100 nm are presented. The photodetectors exhibit excellent long-term stability even stored in air for more than 2 years. These results not only advance the development of high-performance photodetectors based on the graphene/Si Schottky junction, but also have important implications for mass-production of graphene-based photodetector array devices for cost-effective environmental monitoring, medical images, free-space communications, photoelectric smart-tracking, and integration with CMOS circuits for emerging interest-of-things applications, etc.
Antigen presentation is a vital immune process that is essential for T cell immune response triggering. Because T cells recognize only fragmented antigens displayed on cell surfaces, antigen processing must occur before the antigen fragment can be recognized by a T-cell receptor. Specifically, the fragment, bound to the major histocompatibility complex (MHC), is transported to the surface of the antigen-presenting cell, a process known as presentation. If there has been an infection with viruses or bacteria, the antigen-presenting cell will present an endogenous or exogenous peptide fragment derived from the antigen by MHC molecules. There are two types of MHC molecules which differ in the behaviour of the antigens: MHC class I molecules (MHC-I) bind peptides from the cell cytosol, while peptides generated in the endocytic vesicles after internalisation are bound to MHC class II (MHC-II). Cellular membranes separate these two cellular environments - intracellular and extracellular. Each T cell can only recognize tens to hundreds of copies of a unique sequence of a single peptide among thousands of other peptides presented on the same cell, because an MHC molecule in one cell can bind to quite a large range of peptides. Predicting which (fragments of) antigens will be presented to the immune system by a certain MHC/HLA type is difficult, but the technology involved is improving.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.